Statins for acute coronary syndrome
36 results
1 - 36
Statins for acute coronary syndrome 
Statins for acute coronary syndrome Stable (no update expected for reasons given in 'What's new')- Acute coronary syndrome and myocardial infarction
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)- Intensive versus moderate statin therapy
- Early initiation of statins following ACS does not improve outcomes
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Intensive lipid lowering reduces mortality following ACS
- Intensive lipid lowering adds additional benefit
- Coronary heart disease
- Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
- Evacetrapib increases HDL but does nothing for patient-oriented outcomes
- Statin therapy decreases cardiac events
- Small reduction in CV outcome after ischemic stroke with lower LDL target, but also harms; no change in all-cause mortality
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease New search for studies and content updated (conclusions changed)
- Overview of new ACC/AHA lipid guidelines: here we go again
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events New
- Routine or selective invasive strategy for acute coronary syndrome
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- Treatment of dyslipidaemias